Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920773 | 0.94 | NR1H2 (0.44) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| SCHEMBL3931449 | 0.92 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL3918025 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| SCHEMBL3917562 | 0.90 | NR1H2 (0.40) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| Tert-Butanol SCHEMBL3920752 | 0.88 | NR1H2 (0.42) | NR1H2NR1H3SRD5A2TRPV3 | |
| SCHEMBL3921445 | 0.88 | NR1H2 (0.42) | NR1H2NR1H3 | |
| SCHEMBL3983579 | 0.88 | NR1H2 (0.40) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| SCHEMBL3921577 | 0.86 | NR1H2 (0.45) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| SCHEMBL3920962 | 0.86 | NR1H2 (0.45) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 | |
| SCHEMBL3917566 | 0.86 | NR1H2 (0.37) | NR1H2NR1H3SRD5A2MAP2K4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| CN-1894264-A | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1732938-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005058923-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | NR1H2 2030/4885NR1H3 1492/4885SRD5A2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.